Biomarkers for Early Detection of Hematopoietic Malignancies (R21)

The summary for the Biomarkers for Early Detection of Hematopoietic Malignancies (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Biomarkers for Early Detection of Hematopoietic Malignancies (R21): Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages research grant applications from institutions/organizations for the development and validation of biomarkers for: a) early detection, prediction of progression, and recurrence of hematopoietic malignancies, especially in high-risk individuals; and, b) for risk assessment of primary and secondary hematopoietic malignancies. This FOA is also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with hematopoietic malignancies. Mechanism of Support. This FOA will utilize the NIH exploratory/developmental (R21) grant mechanism and runs in parallel an FOA of identical scientific scope, PA-09-197) that encourages applications under the R01 mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.
Federal Grant Title: Biomarkers for Early Detection of Hematopoietic Malignancies (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-09-198
Type of Funding: Grant
CFDA Numbers: 93.393
CFDA Descriptions: Cancer Cause and Prevention Research
Current Application Deadline: Sep 07, 2012
Original Application Deadline: Sep 07, 2012
Posted Date: Jun 01, 2009
Creation Date: Jun 01, 2009
Archive Date: Oct 08, 2012
Total Program Funding:
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Tr...
Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resist...
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial O...
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial O...
Pilot Studies in Pancreatic Cancer
Cancer Prevention Research Small Grant Program
Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Advancing Sustained/Extended Release for HIV Prevention (A-SER) (R01 Clinical Trial Not Al...
Resource-Related Research Projects for Development of Animal Models and Related Materials ...
Tailoring Interventions to Improve Preventive Health Service Use (R61/R33 Clinical Trial R...
Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinica...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com